Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180236 | 0.88 | HDAC1 (0.53) | ALDH1A1GAAGFERABL1ENPP2 | |
| SCHEMBL11976581 | 0.85 | ABL1 (0.46) | NLRP3ALDH1A1MEN1POLBMAPK1 | |
| SCHEMBL30054080 | 0.85 | NLRP3 (0.52) | NLRP3ALDH1A1MEN1POLBMAPK1 | |
| SCHEMBL10420380 | 0.85 | NLRP3 (0.52) | NLRP3ALDH1A1MEN1POLBMAPK1 | |
| SCHEMBL12481099 | 0.84 | NLRP3 (0.48) | NLRP3ALDH1A1MEN1POLBMAPK1 | |
| SCHEMBL10645020 | 0.81 | NLRP3 (0.60) | NLRP3ALDH1A1ABL1ENPP2HPGD | |
| SCHEMBL11977349 | 0.80 | PDE3B (0.55) | NLRP3MEN1POLBMAPK1KMT2A | |
| SCHEMBL29627552 | 0.80 | KDM4E (0.56) | NLRP3ALDH1A1GAAMEN1POLB | |
| SCHEMBL3105331 | 0.80 | KDM4E (0.56) | NLRP3ALDH1A1GAAMEN1POLB | |
| SCHEMBL16413133 | 0.80 | ALDH1A1 (0.48) | ALDH1A1GAAGFERMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606557-B2 | Substituted indoles with inhibitory activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20230192684-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER HIGHER EDUCATION (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192684-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER HIGHER EDUCATION (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192684-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER HIGHER EDUCATION (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021243018-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-12-02 | — | — | WO | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2012102405-A1 | RING-FUSED COMPOUND | 佐藤製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606557-B2 | Substituted indoles with inhibitory activity | IDO1, BCL9, IDO2 | NLRP3 1989/4885ALDH1A1 754/4885GAA 4829/4885 |
| US-20230192684-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | IDO1, IDO2, INMT | NLRP3 1786/4885ALDH1A1 1893/4885GAA 3640/4885 |
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | NLRP3 1156/4885ALDH1A1 487/4885GAA 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.